J Clin Neurol.  2018 Oct;14(4):487-491. 10.3988/jcn.2018.14.4.487.

Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?

• Alonso R
• Eizaguirre MB
• Zavala L
• Pita C
• Silva B
• Garcea O

• KMID: 2424176
• DOI: http://doi.org/10.3988/jcn.2018.14.4.487

Abstract

BACKGROUND AND PURPOSE
The number of disease-modifying drugs (DMDs) available for treating relapsing-remitting multiple sclerosis is increasing. Numerous drugs have been approved since 2010 in South America, which has increased the complexity of the treatment algorithm. The aim of this study was to determine the changes in multiple sclerosis treatments relative to the underlying causes and the availability of new DMDs in Argentina.
METHODS
A descriptive retrospective study was carried out on a group of 59 patients diagnosed with RRMS who use more than one DMD.
RESULTS
The first treatment switch occurred before 2010 in 27% of the patients and after 2010 in the other 73%. Efficacy was the main reason for switching during both periods. A second treatment switch was required in 25% of the patients, with this occurring after 2010 in 86.6% of them. Interferon was the most-used drug before 2010 and fingolimod was the most-used drug thereafter.
CONCLUSIONS
We have identified that the tendency for treatment changes has increased following the arrival of new drugs. Efficacy has been the main cause of these changes.

Keyword

multiple sclerosis; drug therapy; efficacy

MeSH Terms

Argentina
Drug Therapy
Fingolimod Hydrochloride
Humans
Interferons
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting
Retrospective Studies
South America
Fingolimod Hydrochloride
Interferons

Reference

1. Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician. 2004; 70:1935–1944. PMID: 15571060.

2. Fraussen J, Vrolix K, Martinez-Martinez P, Losen M, De Baets MH, Stinissen P, et al. B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun Rev. 2009; 8:654–658. PMID: 19239929.

3. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006; 354:942–955. PMID: 16510748.

4. Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin. 1996; 14:291–308. PMID: 8827172.

5. Polman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. BMJ. 2000; 321:490–494. PMID: 10948033.

6. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987; 317:408–414. PMID: 3302705.

7. Lublin F. History of modern multiple sclerosis therapy. J Neurol. 2005; 252(Suppl 3):iii3–iii9. PMID: 16170498.

8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43:655–661. PMID: 8469318.

9. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69:292–302. PMID: 21387374.

10. Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler. 2009; 15:848–853. PMID: 19542263.

11. Coyle PK. Switching therapies in multiple sclerosis. CNS Drugs. 2013; 27:239–247. PMID: 23508518.

12. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol. 2008; 255(Suppl 1):44–50. PMID: 18317676.

13. Río J, Tintoré M, Sastre-Garriga J, Nos C, Castilló J, Tur C, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. 2012; 19:899–904. PMID: 22289050.

14. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003; 61:1528–1532. PMID: 14663037.

15. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012; 18:932–946. PMID: 22249762.

16. Rio J, Rovira A, Blanco Y, Sainz A, Perkal H, Robles R, et al. [Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score]. Rev Neurol. 2016; 63:145–150. PMID: 27439483.

17. Cristiano E, Alonso R, Alvez Pinheiro A, Bacile EA, Balbuena ME, Ballario C, et al. Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients. J Neurol Sci. 2018; 385:217–224. PMID: 29406907.

18. Carrá A, Onaha P, Luetic G, Burgos M, Crespo E, Deri N, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol. 2008; 15:386–393. PMID: 18353125.

19. Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler. 2012; 18:64–71. PMID: 21828195.

20. Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat Disord. 2015; 4:460–469. PMID: 26346796.

21. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013; 40:307–323. PMID: 23603165.